Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a report issued on Wednesday morning,Benzinga reports. They currently have a $68.00 price objective on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on HALO. Piper Sandler boosted their price target on Halozyme Therapeutics […]

Leave a Reply

Your email address will not be published.

Previous post What is Zacks Research’s Estimate for SYF FY2026 Earnings?
Next post The best snow tubes for thrilling winter rides